Velodyne Lidar Showcases Full Stack Vision Solutions for Robotics, Industrial and Trucking at XPONENTIAL 2022
20.4.2022 13:48:00 EEST | Business Wire | Press release
Velodyne Lidar, Inc. (Nasdaq: VLDR, VLDRW) will demonstrate its innovative lidar sensors and software at XPONENTIAL 2022 in Orlando from April 26 to 28 – booth #2149. Velodyne will highlight how its lidar technology powers autonomous solutions in robotics, industrial, trucking and more that are advancing safety, sustainability, efficiency and equity on a global scale.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220420005427/en/
Velodyne Lidar will demonstrate its innovative lidar sensors and software at XPONENTIAL 2022 – booth #2149. Velodyne will display its cutting-edge Velarray M1600, Puck and Ultra Puck sensors that provide companies the performance, reliability and scalability needed in a wide range of applications. It will also show the Vella Development Kit which allows customers to plug in Velodyne’s lidar with an off-the-shelf library of perception software functions. (Photo: Velodyne Lidar)
Supply chain capacity issues, roadway congestion, safety concerns and labor shortages are driving autonomous system deployments. Velodyne delivers the lidar sensors and software that solve customers’ system-level challenges to develop full-stack autonomous solutions and accelerate their time to market.
At XPONENTIAL, Velodyne will display its cutting-edge Velarray M1600, Puck and Ultra Puck sensors that provide companies the performance, reliability and scalability needed in a wide range of applications. It will also show the Vella Development Kit which allows customers to plug in Velodyne’s lidar with an off-the-shelf library of perception software functions, fast tracking their solution development for ever-evolving applications.
Attendees can immerse themselves in an augmented reality (AR) demonstration to experience how Velodyne’s M1600 sensors perceive the world. Additionally, Velodyne will be joined by Clearpath Robotics, which will showcase its Husky Unmanned Ground Vehicle, powered by Velodyne’s Puck, which is engineered to thrive in harsh outdoor, all-terrain environments.
“XPONENTIAL attendees can see how Velodyne’s sensor and software portfolio is shaping the wave of autonomous solution commercialization taking place in the industrial, robotics and automotive sectors,” said Sally Frykman, Chief Marketing Officer, Velodyne Lidar. “Now more than ever before, we live in a world in motion. To keep pace, industries are deploying smarter technology. Companies can rely on our lidar-based solutions to help their automated systems transform lives and make communities safer.”
How Lidar Solutions Advance Roadway and Supply Chain Efficiency
At the XPONENTIAL conference, Christina Aizcorbe, Velodyne’s Vice President of Government Affairs, will speak on a panel on the commercialization of automated trucking. Mrs. Aizcorbe will discuss how current automated trucking deployments are not just proving out a theoretical concept. They are bringing critical and credible real-world data which will support expansion, making the benefits that will come with commercialization very real to U.S. consumers. Innovation in freight and cargo movement will also spur economic growth well beyond trucking.
The session, called “What Does the Commercialization of Automated Trucking Look Like? – Part 2,” takes place on April 25 from 2:50 p.m. to 3:45 p.m. EDT at Room S330A/B.
“We are seeing rapid growth in automation across other parts of the supply chain, like the use of the same advanced sensing technologies used in automated driving systems to improve efficiency in warehouse and logistics operations, and port automation. Lidar technology is essential to ensuring sensor redundancy and around the clock safe performance of these systems,” said Mrs. Aizcorbe.
To schedule an XPONENTIAL meeting at the Velodyne booth, contact Velodyne Sales: 669.275.2526, sales@velodyne.com.
About Velodyne Lidar
Velodyne Lidar (Nasdaq: VLDR, VLDRW) ushered in a new era of autonomous technology with the invention of real-time surround view lidar sensors. Velodyne, the global leader in lidar, is known for its broad portfolio of breakthrough lidar technologies. Velodyne’s revolutionary sensor and software solutions provide flexibility, quality, and performance to meet the needs of a wide range of industries, including autonomous vehicles, advanced driver assistance systems (ADAS), robotics, unmanned aerial vehicles (UAV), smart cities and security. Through continuous innovation, Velodyne strives to transform lives and communities by advancing safer mobility for all. For more information, visit www.velodynelidar.com.
Forward Looking Statements
This press release contains "forward looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995 including, without limitation, all statements other than historical fact and include, without limitation, statements regarding Velodyne’s target markets, new products, development efforts, and competition. When used in this press release, the words "estimates," "projected," "expects," "anticipates," "forecasts," "plans," "intends," "believes," "seeks," "may," "will," “can,” "should," "future," "propose" and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Velodyne's control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Important factors, among others, that may affect actual results or outcomes include uncertainties regarding government regulation and adoption of lidar, the uncertain impact of the COVID-19 pandemic on Velodyne's and its customers' businesses; Velodyne's ability to manage growth; Velodyne's ability to execute its business plan; uncertainties related to the ability of Velodyne's customers to commercialize their products and the ultimate market acceptance of these products; the rate and degree of market acceptance of Velodyne's products; the success of other competing lidar and sensor-related products and services that exist or may become available; uncertainties related to Velodyne's current litigation and potential litigation involving Velodyne or the validity or enforceability of Velodyne's intellectual property; and general economic and market conditions impacting demand for Velodyne's products and services. For more information about risks and uncertainties associated with Velodyne’s business, please refer to the “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Risk Factors” sections of Velodyne’s SEC filings, including, but not limited to, its annual report on Form 10-K and quarterly reports on Form 10-Q. All forward-looking statements in this press release are based on information available to Velodyne as of the date hereof, Velodyne undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220420005427/en/
Contact information
Velodyne Investor Relations
InvestorRelations@velodyne.com
Media
Codeword
Liv Allen
velodyne@codewordagency.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 15:05:00 EEST | Press release
A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is designed to interpret cardiac MRI scans by connecting moving images of the heart with corresponding clinical radio
The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 15:00:00 EEST | Press release
Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The research challenges long-held assumptions about media value, showing that not all impressions are equal. Live sports rem
Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 15:00:00 EEST | Press release
Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer cell killing activity,” said David Weinreich, MD, MBA, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “The Phase 3 study and the enrollment of the first patient with Precem-TcT build on the Company’s more than 20 years of expertise in colorectal cancer, and highlight our commitment to advancing differentiated ADCs for heavily pretreated patients with limited treatment options.” The PROCEADE®-CRC-03 study
Baszucki Group Funds Oxford University Clinical Trial of Ketogenic Therapy for Early Psychosis21.5.2026 14:00:00 EEST | Press release
Baszucki Group today announced a £1.17 million grant to support a randomized controlled trial at the University of Oxford assessing the feasibility, safety, and efficacy of a ketogenic diet for patients at clinical high risk of psychosis (CHR-P). Researchers will test this nutritional therapy's ability to improve patients' mental and physical health. This project builds on a growing body of research suggesting the potential of metabolic therapies in treating serious mental illness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521877110/en/ Baszucki Group Funds £1.17 Million for University of Oxford Trial of Ketogenic Therapy for Early Psychosis Psychotic disorders carry a massive personal burden and are associated with a lower life expectancy. Psychosis does not develop immediately, but typically emerges following a period of early, subtle symptoms. Individuals in this stage, classified as CHR-P, represent a critical pr
SINOVAC Announces Extension of Deadline to Submit Payment Instructions for Previously Declared Special Cash Dividend21.5.2026 13:30:00 EEST | Press release
Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it has extended the deadline for shareholders and nominee brokers to submit payment instructions relating to the Company’s previously declared special cash dividend. The Company previously announced a special cash dividend of US$55.00 per common share, payable to valid holders of the Company’s common shares as of the close of business on May 23, 2025 ET. The Company previously informed shareholders that completed instruction materials were to be submitted prior to December 31, 2025 in order to facilitate receipt of the dividend. The Company has now extended that submission deadline to June 30, 2026. Shareholders and nominee brokers that have not yet submitted their instruction materials are reminded to do so on or before June 30, 2026 in order to facilitate payment of the dividend. If you have any questions regarding the process you need to un
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
